Current biosensor technologies fail in two critical respects: 1) they can neither process a variety of different samples simultaneous (nor on-the-spot), and 2) there is no ability to perform continuous, real-time monitoring of important biomarkers. Across a spectrum of laboratory and clinical settings, the market for immediate, multiplex, biomarker measurement is huge. Vista's technology has both of the above capabilities, and it will change how the world measures biomolecules.

The ability to prepare and simultaneously measure many biomarkers is useful in contexts where one must perform a large number of varying tests in a short time, such as emergency rooms, and for drug testing in large institutions (such as prisons, in the workplace, or at the border). The fact that Vista's kits are straightforward to use further facilities high-volume, multiplex testing. The ability to perform real-time, near-continuous monitoring will be well appreciated in the ICU, for optimizing patient drug doses, for maximizing benefits during renal dialysis, and for monitoring both molecular exposure and performance in high-stress situations, including warfare.

The illustration below suggests how real-time data regarding molecular concentrations in a patient's blood might be useful during intensive care. There, timely knowledge of critical (but rapid and short-lived) cascades of biomarkers in the serum can help quickly direct staff to appropriate interventions. Of course, more generally, real-time measurement will also be useful in identifying physiological trends, monitoring the benefits of therapeutic interventions, avoiding unacceptable levels of drug toxicity, and, overall, individualizing treatments.

To meet these two unmet needs, Vista will market simple, accurate, easy-to-use assays and equipment that allow ongoing monitoring of biomarkers in bodily fluid for use in animal research and for clinical use. Our NanoBioSensor™ systems will include microfluidics/nanowire chips, reagents and disposable plastics, and an electronic sensor that reads and interprets results. Clients can request any combination of probes for biomarkers, including AB’s, enzymes, small-molecules and oligonucleotides. In addition, Vista will provide nanowire-based contract research through co-marketing agreements with large or specialty CRO’s and clinical trials organizations.

Vista has longer range plans (because they require FDA approval) for Intensive Care Unit systems and, at some point, even simpler systems for AT-Home use by the end-patient themselves (analogous to at-home pregnancy tests).

(For a more detailed descriptions of what Vista is in the process of bringing to market, refer to the section of our website that describes Products and Prototype.)

Estimates of USA market opportunities that do not require FDA approval are shown below:

We estimate the that upon FDA approval of the system technology (and it is hardly intrusive or dangerous), the USA market would jump to approximately $13 billion.